Business
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company’s outstanding
About this update from Alaunos Therapeutics, Inc.
[{"type":"image","alt":"PMGC Holdings Inc.","displaySize":"","headline":null,"caption":"PMGC Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":243,"url":"https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FeIekmuAEqql.btYh_OPxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7","width":300,"height":243}},"lazy":false},{"type":"text","content":"NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT).","length":372,"tagName":"p"},{"type":"text","content":"PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company’s outstanding shares of common stock, based on Alaunos' Preliminary Schedule 14A filed with the U.S. Securities and Exchange Commission, indicating 1,639,521 shares of common stock outstanding as of May 5, 2025.","length":328,"tagName":"p"},{"type":"text","content":"Alaunos Therapeutics, Inc. (“Alaunos Therapeutics” or “Alaunos”), headquartered in Houston, Texas, is a clinical-stage oncology-focused cell therapy company. Alaunos is currently exploring strategic alternatives, including but not limited to acquisitions, mergers, reverse mergers, sale of assets, strategic partnerships, capital raises, or other transactions.","length":360,"tagName":"p"},{"type":"text","content":"PMGC Capital believes Alaunos is undervalued and has significant potential to create shareholder value. PMGC Capital intends to engage constructively with Alaunos’ management and board of directors to explore strategic opportunities, including potential mergers, acquisitions or partnerships in sectors such as financial technology and cryptocurrency.","length":351,"tagName":"p"},{"type":"text","content":"We commend Alaunos Therapeutics for maintaining a clean capital structure and exercising prudent financial stewardship during challenging market conditions. PMGC Capital looks forward to collaborating with t...